NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
A new cancer vaccine, mRNA-4359, utilizing mRNA technology similar to Covid-19 vaccines, has yielded encouraging results in ...
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
If you’ve received the COVID-19 vaccine, you may have experienced common side effects such as pain, fatigue, or fever, or ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.
NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...
Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.